ALFA Finder| Revenue growth | Q2 +16.2% YoY; H1 +17.8% YoY |
|---|---|
| Margins | EBITDA margin 21.0%, down 110 bps YoY; gross 53.7% |
| Demand visibility | Emerging markets, India +39% each; API demand rising |
| Management confidence | CEO calls quarter 'stellar'; stresses disciplined execution |
Growth
Q2 revenue +16.2% YoY: formulations +19%, APIs +12%, emerging markets +39%. H1 revenue +17.8% to ₹1,934 Cr.
Outlook
No numeric guidance given. Ambernath companion-animal plant commissioning Q1 FY28. Nalgonda API block adds 128 KL capacity.
Risks
USA sales fell 11% YoY. EBITDA margin down 110 bps; gross margin 53.7% vs 55.5%. ESOP cost rose to ₹42 Cr from ₹10 Cr.
Last quarter's promises, checked
Delivered
- Guided double-digit growth → Q2 rev +16.2% (= BEAT)
- Guided Italy close in 2-3 mo → closed 1 Oct 2026 (= BEAT)
- Guided EBITDA margin 20-22% → 21.0% (= BEAT)
Partly delivered
- Guided API growth 13-15% FY27 → Q2 APIs +12% (= PARTIAL, FY pending)
Missed
- Guided plant ready Jan-Feb'27 → commissioning Q1 FY28 (= MISS)
- Guided ESOP ~Rs40 Cr/qtr → Rs42 Cr (= MISS)
- Said US 'confident to grow' → USA sales -11% YoY (= MISS)
Investor Presentation filed with BSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹255.32
- Market cap
- ₹11,285 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 48.5×Sector 43.7×
- Promoter holding
- 49.24%-12.07% QoQ
- FII holding
- 2.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Results Update
Viyash Scientific's Q2 FY27 press release shows H1 revenue up 17.8% and PAT up 49%. An earnings call is scheduled for 14 November 2026.
Viyash Scientific Q2 FY27 Results: Net Profit ₹84.7 Cr, Up 16.2% YoY
Viyash Scientific Ltd filed unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Standalone revenue from operations was INR 3,906.50 million for the quarter.
- Key figure
- Net profit ₹84.7 Cr · +16.2% YoY
Viyash Scientific Employee Stock Options
Viyash Scientific allotted 228,408 shares under two employee stock option schemes. Paid-up capital rose to 44,19,91,958 shares of Rs.2 each.
Viyash Scientific Board Meeting Date
Viyash Scientific will hold a board meeting on 13 November 2026 to consider unaudited quarterly and half-yearly results. The trading window remains closed until 15 November 2026.
Viyash Scientific Merger & Restructuring Worth ₹3.8 Cr
Viyash's step-down subsidiary Alivira Vietnam was incorporated on 30 October 2026, with investment up to USD 400,000. It will distribute animal health products and APIs in Vietnam.
- Value
- ₹3.80 Cr
Viyash Scientific Management Change
Viyash Scientific Limited has appointed Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, succeeding the retiring Mr. Prasad Lad.